ライフサイエンスコーパス: acute hepatitis C

1 longitudinally from the time of diagnosis of acute hepatitis C.

2 as playing a critical role in the outcome of acute hepatitis C.

3 egylated interferon alfa-2b for treatment of acute hepatitis C.

4 We identified 20 participants with acute hepatitis C (10 with hepatitis C virus [HCV] monoi

5 to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P < .05).

6 Of 45 patients with acute hepatitis C, 40.0% were simultaneously infected wi

7 Therapy of acute hepatitis C (AHC) has not yet been standardized an

8 Treatment of patients with acute hepatitis C (AHC) is more effective, with sustaine

9 ortion of HIV(+) patients manage to overcome acute hepatitis C (AHC) spontaneously.

10 ease resolution in a cohort of patients with acute hepatitis C (AHC), analyzing epidemiological, clin

11 els of IP-10, with outcomes of patients with acute hepatitis C (AHC).

12 We examined trends in incidence of acute hepatitis C among young persons reported to the Ce

13 e epidemiologically distinct from those with acute hepatitis C and have a significantly more severe a

14 are essential for spontaneous resolution of acute hepatitis C and long-term protection from persiste

15 emed essential for spontaneous resolution of acute hepatitis C and long-term protection.

16 Patients with acute hepatitis C and schistosomiasis coinfection cannot

17 Acute hepatitis C and spontaneous clearance was also ass

18 Acute hepatitis C and spontaneous clearance was associat

19 ants identified from the Australian Trial in Acute Hepatitis C and the Networks study were followed l

20 cal correlates of clearance in patients with acute hepatitis C and their sexual contacts.

21 Further, PBMC from patients with acute hepatitis C as well as HCV-infected Huh7.5 cells h

22 The Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of the

23 ubjects, enrolled in the Australian Trial in Acute Hepatitis C (ATAHC), using HCV peptide enzyme-link

24 markedly prolonged the incubation period of acute hepatitis C but did not prevent or delay HCV infec

25 covery occurs in a minority of patients with acute hepatitis C but is associated with vigorous and lo

26 Clinically, acute hepatitis C can increase concentrations of alanine

27 ceptor (TLR) expression and signaling during acute hepatitis C correlates with clinical outcomes.

28 Approximately 85% of persons with acute hepatitis C develop chronic hepatitis as determine

29 nclude that approximately 85% of people with acute hepatitis C develop persistent viremia.

30 Acute hepatitis C developed in both the IGIV-treated and

31 ells from healthy controls and patients with acute hepatitis C efficiently recognized both HCV-infect

32 Although the incidence of acute hepatitis C has declined, there is a large reservo

33 Approximately three quarters of acute hepatitis C (HCV) infections evolve to a chronic s

34 virin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population.

35 d the efficacy of PEG IFN-alpha treatment in acute hepatitis C in relation to the kinetics of hepatit

36 mately 10% of persons with reported cases of acute hepatitis C in the United States report a history

37 Reports of acute hepatitis C in young persons in the United States

38 From 2006 to 2012, reported incidence of acute hepatitis C increased significantly in young perso

39 Peginterferon alfa-2b monotherapy in acute hepatitis C induces high sustained virologic respo

40 s with FPAs were compared with patients with acute hepatitis C infection without FPAs.

41 In acute hepatitis C infection, close monitoring of hepatit

42 There is a paucity of information on core in acute hepatitis C infection.

43 od samples from participants in the Montreal Acute Hepatitis C Injection Drug User Cohort Study who w

44 Our results show that the outcome of acute hepatitis C is associated with a functional hierar

45 The outcome of acute hepatitis C is associated with efficient virus-spe

46 Acute hepatitis C is marked by appearance of HCV RNA in

47 Acute hepatitis C is most often diagnosed in the setting

48 chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action

49 Mechanisms by which spontaneous clearance of acute hepatitis C occurs are unclear.

50 Symptomatic acute hepatitis C occurs in only about 15% of patients w

51 A patient developed acute hepatitis C shortly after tissue transplantation.

52 Compared with patients with acute hepatitis C, those with non-ABCDE hepatitis had a

53 ve used this resource to study parameters of acute hepatitis C virus (HCV) infection among 94 donor-r

54 r (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (

55 e a patient with hypogammaglobulinemia whose acute hepatitis C virus (HCV) infection appeared to reso

56 Outbreaks of acute hepatitis C virus (HCV) infection are occurring in

57 Acute hepatitis C virus (HCV) infection becomes chronic

58 Acute hepatitis C virus (HCV) infection culminates in vi

59 Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spon

60 sequelae during the first two decades after acute hepatitis C virus (HCV) infection have been well s

61 tween IL28B and the clinical presentation of acute hepatitis C virus (HCV) infection in a homogeneous

62 Fibrosis progression after acute hepatitis C virus (HCV) infection in human immunod

63 ness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunod

64 Acute hepatitis C virus (HCV) infection is often asympto

65 Acute hepatitis C virus (HCV) infection is rarely studie

66 Acute hepatitis C virus (HCV) infection is underdiagnose

67 Treatment of acute hepatitis C virus (HCV) infection leads to a susta

68 une responses during the first few months of acute hepatitis C virus (HCV) infection seem crucial for

69 guidelines now recommend that patients with acute hepatitis C virus (HCV) infection should be treate

70 Acute hepatitis C virus (HCV) infection was the final di

71 Historically, acute hepatitis C virus (HCV) infection was treated with

72 over, these cells were highly permissive for acute hepatitis C virus (HCV) infection, and persistent

73 e thought to be important for the control of acute hepatitis C virus (HCV) infection, but to date lit

74 In acute hepatitis C virus (HCV) infection, programmed deat

75 In the setting of acute hepatitis C virus (HCV) infection, robust HCV-spec

76 In studies of acute hepatitis C virus (HCV) infection, the early host

77 c liver disease may develop many years after acute hepatitis C virus (HCV) infection, the past incide

78 e early events that determine the outcome of acute hepatitis C virus (HCV) infection, we compared the

79 are the hallmark of spontaneous clearance of acute hepatitis C virus (HCV) infection, whereas compara

80 ics and evolution predict outcome of primary acute hepatitis C virus (HCV) infection.

81 therapy has not been adequately evaluated in acute hepatitis C virus (HCV) infection.

82 variation is a determinant of recovery from acute hepatitis C virus (HCV) infection; however, to dat

83 estigation was to prospectively characterize acute hepatitis C virus (HCV) infections and to evaluate

84 States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined fr

85 Acute hepatitis C virus (HCV) is typically defined as ne

86 ered for 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a total of 161 patient

87 Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, a

88 These findings indicate that, during acute hepatitis C virus infection in vivo, virus-specifi

89 ed virologic response rates in patients with acute hepatitis C virus infection, thus preventing devel

90 a total of 161 patients were identified with acute hepatitis C virus infection.

91 ther these observations indicate that during acute hepatitis C, virus evolution was driven primarily

92 ks in addition to 14 untreated subjects with acute hepatitis C were prospectively followed.

93 and immunological studies on 7 patients with acute hepatitis C who received antiviral therapy and wer

94 Forty subjects with proven acute hepatitis C who received either PEG IFN-alpha plus